Guided Therapeutics completes patient enrollment for FDA trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall St set for subdued open on final trading day of strong quarter
- Strong dollar pushes yen to 40-year low as traders test Japanese authorities
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Logitech dips as BofA downgrades stock on demand outlook concerns
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial
August 13, 2025 9:00 AM EDTPEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today that it had enrolled enough patients to begin closing out the study and starting data analysis. Data analysis will consist of completing the ongoing external review of all biopsy samples, reviewing and entering data from the study case report forms and performing the statistical analysis pursuant to the study protocol. All four participating clinics have reached their minimum specified quotas... More
